Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01659385
Other study ID # 0276-12-EP
Secondary ID
Status Completed
Phase
First received
Last updated
Start date August 7, 2012
Est. completion date April 25, 2013

Study information

Verified date August 2023
Source University of Nebraska
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The purpose of this study is to evaluate Leptin levels in females, in the setting of papillary thyroid cancer, benign thyroid nodules, and in normal females without thyroid disease.


Description:

There will be three groups in this study, but 2 of the groups are part of another study so will only recruit normal controls.


Recruitment information / eligibility

Status Completed
Enrollment 18
Est. completion date April 25, 2013
Est. primary completion date April 25, 2013
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 19 Years to 75 Years
Eligibility Inclusion Criteria: - Female - Age>/- 19 - Not currently pregnant or lactating - Normal thyroid gland by history Exclusion Criteria: - Male Gender - Pregnancy - Lactation - Age below 19 - Abnormal thyroid gland by history - Abnormal thyroid gland by structure using ultrasound - Abnormal thyroid gland by function using TSH, Free T4

Study Design


Locations

Country Name City State
United States University of Nebraska Medical Center Omaha Nebraska

Sponsors (1)

Lead Sponsor Collaborator
University of Nebraska

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary evaluating Leptin level Evaluating Serum Leptin Levels Between 3 Groups. One Group with Papillary Thyroid Carcinoma. One Group With Benign Nodules. One Group with Normal Thyroid. Assessing serum leptin levels in females with treated papillary thyroid carcinoma and compared to females with proven benign thyroid nodules and females with normal thyroid glands. All groups were matched by gender, age, and BMI to limit confounders. During Study
See also
  Status Clinical Trial Phase
Completed NCT06439745 - More Than 50% of the Patients With Clinically Unifocal T1b/Small T2 Node Negative Papillary Thyroid Carcinoma Scheduled for Thyroid Lobectomy May Require Completion Thyroidectomy if the Nodal Status is Evaluated
Recruiting NCT02952612 - Active Surveillance of Papillary Thyroid Microcarcinoma N/A
Recruiting NCT05247476 - Type 2 Deiodinase Gene Polymorphism and the Treatment of Hypothyroidism Caused by Thyroidectomy in Thyroid Cancer Patients. Phase 4
Completed NCT04594720 - Circulating Biomarkers to Identify Thyroid Cancer
Terminated NCT04644315 - A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors Phase 2
Recruiting NCT04396912 - Post-thyroidectomy Vocal Cord Paralysis Along With Hypocalcemia: STROBE - Guided Prospective Cohort
Enrolling by invitation NCT04411290 - Malignancy Predictors, Bethesda and TI-RADS Scores Correlated With Final Histopathology in Thyroid Diseases
Completed NCT03037385 - Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06254859 - Intraoperative Neuromuscular Monitoring and Its Impact on Pre- and Postoperative Acoustic Outcomes in Thyroid Surgery
Recruiting NCT05768178 - DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers. Phase 2/Phase 3
Completed NCT06068101 - Clinical and Genetic Investigation of the Association Between Primary Aldosteronism and Thyroid Cancer
Completed NCT04462471 - Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers Phase 1
Recruiting NCT04985604 - Tovorafenib (DAY101) Monotherapy or in Combination With Other Therapies for Patients With Melanoma and Other Solid Tumors Phase 1/Phase 2
Recruiting NCT05796960 - European Multicenter Study on Surgical Management of Advanced Thyroid Cancer
Completed NCT02418390 - The Efficacy and Safety of Prophylactic Central Lymph Node Dissection in Papillary Thyroid Carcinoma N/A